Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oo Bohomolets Nat MedicalfiledCriticalUniv Oo Bohomolets Nat Medical
Priority to UA20041210310UpriorityCriticalpatent/UA6872U/en
Publication of UA6872UpublicationCriticalpatent/UA6872U/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Peptides Or Proteins
(AREA)
Abstract
The method for treating the optic neuropathy in demyelination diseases comprises the use of the traditional anti-inflammatory and symptomatic treatment. The preparation possessing anti-inflammatory, anti-infectious, immunoregulation, and substituting activities "Normal human immunoglobulin for intravenous injections" manufactured by closed joint-stock company Biopharma is used for such a treatment.
UA20041210310U2004-12-152004-12-15Method for treating optic neuropathy in demyelination diseases
UA6872U
(en)
USE OF SPECIAL FORMYLATED CHINOLINIUM DERIVATIVES IN COMBINATION WITH AMINO-SUBSTITUTED DIARYL DERIVATIVES AND AT LEAST ONE OTHER PRIMARY OR SECONDARY AROMATIC AMINE